Medivir

Medivir Operating Cash Flow

The Operating Cash Flow of Medivir (MVIR.ST) as of Nov 5, 2026 is -73.35 M SEK. In the previous year, Operating Cash Flow was -124.19 M SEK — a change of -40.94% (higher).

Operating Cash Flow

-73.35 MSEK

YoY

-40.94%

Last updated:

Operating Cash Flow of Medivir is 2025 -73.35 M SEK. Operating Cash Flow of Medivir was 2024 -124.19 M SEK. It decreases by -40.94% higher compared to the previous year.

The Medivir Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-318.63 M SEK
Jan 1, 2019
-148.26 M SEK
Jan 1, 2020
-58.05 M SEK
Jan 1, 2021
-48.73 M SEK
Jan 1, 2022
-101.82 M SEK
Jan 1, 2023
-59.67 M SEK
Jan 1, 2024
-124.19 M SEK
Jan 1, 2025
-73.35 M SEK
The Medivir Operating Cash Flow history
YEAROperating Cash FlowYoY
-73.35 MSEK-40.94%
-124.19 MSEK+108.15%
-59.67 MSEK-41.40%
-101.82 MSEK+108.93%
-48.73 MSEK-16.05%
-58.05 MSEK-60.84%
-148.26 MSEK-53.47%
-318.63 MSEK-11.12%
-358.48 MSEK+96.66%
-182.28 MSEK-159.30%
307.39 MSEK-69.70%
1.01 BSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Operating Cash Flow of Medivir is -73.35 M SEK in 2025.

Operating Cash Flow of Medivir changed from -124.19 M SEK to -73.35 M SEK, representing a -40.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Medivir since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Medivir historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medivir

All Key Metrics — Medivir